Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers. - Wikidata - wikimedia - TriplyDB

Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers.

Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers.

http://www.wikidata.org/entity/Q46562534

about

Endothelin receptor antagonists for pulmonary arterial hypertension Guanylate cyclase stimulators for pulmonary hypertension Treatment of patients with chronic thrombo embolic pulmonary hypertension: focus on riociguat The limits of oral therapy in pulmonary arterial hypertension management Heme-dependent and independent soluble guanylate cyclase activators and vasodilation.Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study.Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension.Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease Absorption of riociguat (BAY 63-2521): bioavailability, food effects, and dose proportionality.Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food.Leads for the treatment of pulmonary hypertension.Riociguat for pulmonary hypertension.Riociguat for the treatment of pulmonary hypertension.Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.Stimulators of soluble guanylyl cyclase: future clinical indications Riociguat: first global approval.Riociguat for pulmonary hypertension.Riociguat for the treatment of pulmonary hypertension.Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension.The safety and effectiveness of riociguat to treat chronic thromboembolic pulmonary hypertension.Riociguat: a novel new drug for treatment of pulmonary hypertension.New pharmacotherapy options for pulmonary arterial hypertension.Riociguat for the treatment of pulmonary hypertension.Riociguat for the treatment of pulmonary hypertension: a safety evaluation.Contemporary Approaches to Modulating the Nitric Oxide-cGMP Pathway in Cardiovascular Disease.Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study.Effects of omeprazole and aluminum hydroxide/magnesium hydroxide on riociguat absorption Riociguat (BAY 63-2521) and aspirin: a randomized, pharmacodynamic, and pharmacokinetic interaction study.Pharmacokinetic interaction of riociguat with ketoconazole, clarithromycin, and midazolam The sGC stimulator riociguat inhibits platelet function in washed platelets but not in whole blood.Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).

P2860

Q24200714-6D03E09D-0792-4619-B6CA-999FDBDB42CB Q26470534-A68AA9D7-CB27-4BFF-B8B1-5F64835553DC Q26746202-BA3F35A2-6029-4F54-B733-D259EF26C367 Q26773209-4551B3E3-F497-4CCC-808E-48A61641D151 Q27692662-A354B2A3-1F61-4D33-B5D7-193F5C323D5D Q33447738-BDDDF704-9119-4591-9705-3BA909790FE7 Q33532813-CC9D24E2-A65D-429F-B71A-6B39AF8DD498 Q33596457-D6AD5D92-C9D0-4D04-AA8C-EBB460C22C75 Q34179857-87391782-92F9-4F76-B062-276A16F13CAE Q34444990-F33F8CC9-24E8-4157-8279-F3C3F3D23CF8 Q35010064-B7F6F3AF-58E5-40B2-AE70-2EBFC4921C3A Q35075847-33B6A0D3-820B-442C-9077-4F16C324FB7B Q35665739-FB23C8EB-E338-427D-8CBB-C8C2EABC9C83 Q36734217-01F7A329-1045-479D-B449-8523F3A8FBCF Q36881692-B879ED63-2C65-4B54-8EA0-05D41F745CC9 Q36881704-EBFA52A8-55C2-4F1B-A202-A88A3627323D Q36881715-103291A4-0324-4ECF-AFE3-56C5441A7A8C Q36881722-346659A4-8D7E-49ED-9CFE-BAF0C88BB119 Q36881733-EC1D4879-939C-475A-8C7C-5785EF067D0F Q37481343-B4E6AD9A-EF29-4089-B7ED-D22F4CDA3717 Q37709398-2404B289-ABE6-4AB7-B03E-0B6D75C58876 Q37851516-8F99D5EB-84DC-4314-9AE1-D730CDD14216 Q38000562-D80E0620-16CD-4E25-B9FA-E54FC94A22C7 Q38093420-867051D0-33E0-4C29-9F76-7CEF44555FE0 Q38161841-F2A5AE70-DC9E-4823-9E50-CAD287C419FC Q38192059-FE7AA670-FF83-42D9-B979-E4BE7DAE36CA Q38254736-6FC95874-15D8-43D4-8C0A-0966F706FFA9 Q38263468-0FC0193D-7B03-444B-9108-91D5E7045B47 Q38386942-5881C7A7-1D9F-4591-AD57-6612F1A44D08 Q38502798-FE8E1DCF-F16C-400B-B3DB-E1A015EEDDB6 Q38569940-3DA8B837-4628-4357-9D5E-D06628BC7E19 Q38645382-AED12976-1DA9-4760-81CE-3A7DC79299A9 Q38983098-11683DFF-CA41-4A89-A593-F06A3B917B97 Q39209626-6803F0D9-4274-4744-A660-35911904C170 Q40386143-E89B0854-71C8-41EB-88A7-49325B11CCBB Q41165804-A58E8924-95BA-42D2-9533-A1A110596C75 Q41166010-53848313-3DA9-4CE3-8E5F-6CDC08319E45 Q41166308-A329A5C0-0BB5-4D21-83D5-C9C89F29097B Q43119916-2EFECF91-1295-4CBC-AAAC-50CED221BBA9 Q45811750-CDB7043D-CE13-41F2-9DE1-39DA95995ECA

P2860

Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers.

http://www.wikidata.org/entity/Q46562534

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Single-dose pharmacokinetics, ...... dy in healthy male volunteers.

@en

Single-dose pharmacokinetics, ...... dy in healthy male volunteers.

@nl

type

label

Single-dose pharmacokinetics, ...... dy in healthy male volunteers.

@en

Single-dose pharmacokinetics, ...... dy in healthy male volunteers.

@nl

prefLabel

Single-dose pharmacokinetics, ...... dy in healthy male volunteers.

@en

Single-dose pharmacokinetics, ...... dy in healthy male volunteers.

@nl

P1433

Q46562534-0EAB1BDE-AA7F-4231-89F7-0C034156C41C

P1476

Q46562534-FDA6BCAF-A73F-4FC1-B736-5AC4E09F520A

P2093

Q46562534-0C8D11DC-C338-4128-B29A-610D003232DA

Q46562534-28F2538C-2102-4781-A3C2-43684C5E7678

Q46562534-32E0EB80-0216-40B1-B4B0-7DA6ED9955E3

Q46562534-544DF0F1-3312-4776-9CC6-9AB1B8784680

Q46562534-608E6D59-6FFB-4CE7-8D16-33222C054030

Q46562534-AD0BF135-43EF-4A50-BEE7-39D1B56F492B

P2860

Q46562534-095D3A98-8557-414E-90C5-C66BB6DF9CF3

Q46562534-0F02B9B1-39C0-4387-B62B-6EDE69561AC0

Q46562534-325EA572-2167-495F-93C2-65131FA05F4C

Q46562534-4CA2BCC7-916F-49AF-93E4-4D975A4E7B86

Q46562534-5846A0E9-F78B-46A6-8078-60D5C613BCA0

Q46562534-60E259B3-5C87-41DB-AB5A-CC6D7595C44E

Q46562534-63F1D06F-30DF-44AD-BB19-D94D902C749D

Q46562534-65C8A872-B2DA-4683-B51E-842C50FFB83D

Q46562534-69C2BC73-D18A-4937-A998-3A10CEE356B6

Q46562534-728F5CE7-9991-4127-8EE4-65DB5009FFEF

P304

Q46562534-E6581A36-47D2-47D2-ACD1-7B944F359BD2

P31

Q46562534-70A6D341-534E-41ED-8F74-4AF4E035DEE2

P356

Q46562534-D3985732-14EC-4684-8C91-C768164F6661

P433

Q46562534-2C284309-B73A-425D-B54D-D74308761242

P478

Q46562534-62E878D5-1948-4441-A564-D49A239DC603

P577

Q46562534-0FB051B9-FF44-4F87-8863-711CB3385976

P5875

Q46562534-1077AF93-323F-4856-83CA-24859013E6F3

P698

Q46562534-E4FD3C5A-1E2B-438B-81F3-19D9E18ACBB8

P356

0091270008319793

P1433

The Journal of Clinical Pharmacology

P1476

Single-dose pharmacokinetics, ...... dy in healthy male volunteers.

@en

P2093

Georg Wensing

http://www.w3.org/2001/XMLSchema#string

Gerrit Weimann

http://www.w3.org/2001/XMLSchema#string

Reiner Frey

http://www.w3.org/2001/XMLSchema#string

Sigrun Unger

http://www.w3.org/2001/XMLSchema#string

Ulrike Artmeier-Brandt

http://www.w3.org/2001/XMLSchema#string

Wolfgang Mück

http://www.w3.org/2001/XMLSchema#string

P2860

NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential

Management of pulmonary arterial hypertension with a focus on combination therapies.

Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations.

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

Inhaled iloprost for severe pulmonary hypertension.

Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension.

Sildenafil citrate therapy for pulmonary arterial hypertension.

Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels

The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension.

Explaining the phenomenon of nitrate tolerance.

P304

926-934

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0091270008319793

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2008-06-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51396503

http://www.w3.org/2001/XMLSchema#string

P698

18519919

http://www.w3.org/2001/XMLSchema#string